Figure 1.

Effect of different schedules of combination of pemetrexed (PEM) with carboplatin (CARBO) (A), gemcitabine (GEM) (B), or mitomycin C (MITOC) (C) on three colon cancer cells lines. Cell viability was determined by SRB assay, and the results were expressed as the mean of an octuplicate from three independent experiments. Bars represent standard deviation (*p < .05). Statistical significance was determined using the GraphPad Prism Software Holm‐Sidak method. Treatment dose: #1 (PEM 1 mM ‐ CARBO 0.8 mM), #2 (PEM 10 mM ‐ CARBO 8 mM), #3 (PEM 100 mM ‐ CARBO 80 mM), #4 (PEM 1 mM ‐ GEM 0.4 mM), #5 (PEM 10 mM ‐ GEM 4 mM), #6 (PEM 100 mM ‐ GEM 40 mM), #7 (PEM 1 mM ‐ MITOC 0.03 mM), #8 (PEM 10 mM ‐ MITOC 0.3 mM), and #9 (PEM 100 mM ‐ MITOC 3 mM).

Abbreviations: CARBO, carboplatin; GEM, gemcitabine, MITOC, mitomycin C; SRB, sulforhodamine B; WO, wash‐out.